Market News AIOpen the app

Mira Pharmaceuticals shared new findings about its drug MIRA-55, which may help treat inflammatory pain without opioids.

TrialRead the original at SEC EDGAR
Good for MIRA

Mira Pharmaceuticals reported receptor tests showing more than 500-fold separation from opioid receptors and no substantial COX-1 or COX-2 inhibition. This supports a distinct approach to pain treatment, but MIRA-55 is still in preclinical work.

MIRA · Mira Pharmaceuticals, Inc.

AI read · Good for MIRA

The AI's read

That separation could help distinguish MIRA-55 from common pain medicines. Earlier animal studies reported pain relief and reduced inflammation, including results compared with morphine and celecoxib. But no human results are reported, and the company is still preparing an application to begin human testing, targeted for the first half of 2027. The findings favor continued development, though they do not show whether the drug will work in people.

Get alerts for MIRA

Follow Mira Pharmaceuticals, Inc. (MIRA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MIRA
Free on the App Store and Google Play, or on the web.